



## Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience

John F. Marcinak<sup>1</sup>  · Melvin S. Munsaka<sup>1</sup> · Paul B. Watkins<sup>2</sup> · Takashi Ohira<sup>3</sup> · Neila Smith<sup>1</sup>

Published online: 17 October 2018  
© Springer Nature Switzerland AG 2018

**Correction to: Drug Saf**  
<https://doi.org/10.1007/s40264-018-0642-6>

In the original publication of the article, the ALT and AST values in Fig. 5a–e were capped at 10× ULN, which did not accurately reflect the narrative provided for each case. In this correction, the original Fig. 5a–e (Fig. 1a–e) and the correct Fig. 5a–5e (Fig. 2a–e) are published.

---

The original article can be found online at <https://doi.org/10.1007/s40264-018-0642-6>.



---



✉ John F. Marcinak  
[john.marcinak@takeda.com](mailto:john.marcinak@takeda.com)

<sup>1</sup> Takeda Pharmaceuticals, Takeda Development Center Americas, Inc., 1 Takeda Pkwy, Deerfield, IL 60015, USA

<sup>2</sup> Eshelman School of Pharmacy, Institute for Drug Safety Sciences, University of North Carolina, Chapel Hill, NC, USA

<sup>3</sup> Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, Japan












Fig. 1a–e Original version of Fig. 5a–e as published on 28 February 2018








Fig. 2a-e Corrected version of Fig. 5a-e